European Crohn´s and Colitis Organisation - ECCO - Past Congresses
ECCO 2022
Biotherapy monitoring, a major area of interest at the European Crohn's and Colitis Organisation (ECCO) Congress
European Crohn's and Colitis Organisation (ECCO) 2016 Congress
European Crohn´s and Colitis Organisation - ECCO - Fellowships and Grants
The biosimilar landscape
European Crohn´s and Colitis Organisation - ECCO - Past Congresses
European Crohn´s and Colitis Organisation - ECCO - Congresses & Events
ECCO 2017 Congress – Save the Date :: SIOP Europe
European Crohn´s and Colitis Organisation - ECCO - Published ECCO Guidelines
conference reportPeer-reviewed
European Crohn´s and Colitis Organisation - ECCO - Congresses & Events
Previous exposure to biologics and C-reactive protein are associated with the response to tacrolimus in inflammatory bowel dise
European Crohn's and Colitis Organisation (ECCO) 2016 Congress
European Crohn´s and Colitis Organisation - ECCO - Past Congresses
Targeting Disease Progression in Crohn's Disease: Fighting an Unrelenting Enemy - European Medical Journal
European Crohn´s and Colitis Organisation - ECCO - Why become a Corporate Member
ECCO IBD by OCEAiN Organisation, Congress, Emotion, Association, iNnovation GmbH
European Crohn´s and Colitis Organisation - ECCO - Congresses & Events
ECCO EFCCA Patient Guidelines | efcca.org
European Crohn´s and Colitis Organisation - ECCO - Home
European Crohn´s and Colitis Organisation - ECCO - ECCO News
ECCO 2022
European Crohn's and Colitis Organisation (ECCO) 2016 Congress
Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study
Data presented at ECCO congress supports switching from Remicade® to biosimilar infliximab - Hospital Pharmacy EuropeHospital Pharmacy Europe
